Quick Answer
Moleculin Biotech, Inc. reported Total Assets of $22.13 million for the year ending 2025.
- Moleculin Biotech, Inc. showed an increase of +30.7% in Total Assets from 2024 to 2025.
- This data is from Moleculin Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $289.7 thousand | Q2 2016: $19.23 million | Q3 2016: $17.57 million | Q1 2017: $20.32 million | Q2 2017: $21.25 million | Q3 2017: $20.63 million | Q1 2018: $24.93 million | Q2 2018: $24.07 million | Q3 2018: $20.90 million | Q1 2019: $21.30 million | Q2 2019: $31.85 million | Q3 2019: $30.40 million | Q1 2020: $25.47 million | Q2 2020: $31.38 million | Q3 2020: $27.14 million | Q1 2021: $99.78 million | Q2 2021: $93.53 million | Q3 2021: $88.70 million | Q1 2022: $78.80 million | Q2 2022: $73.26 million | Q3 2022: $65.37 million | Q1 2023: $51.06 million | Q2 2023: $47.12 million | Q3 2023: $39.52 million | Q1 2024: $30.85 million | Q2 2024: $25.58 million | Q3 2024: $23.39 million | Q1 2025: $21.01 million | Q2 2025: $21.59 million | Q3 2025: $20.35 million.
- Over the full 11 years of available data (2015 to 2025), Moleculin Biotech, Inc.'s Total Assets has grown by 78,665.4%.
- Historical annual values: Fiscal year 2025: $22.13 million | Fiscal year 2024: $16.93 million | Fiscal year 2023: $38.22 million | Fiscal year 2022: $57.42 million | Fiscal year 2021: $84.09 million | Fiscal year 2020: $29.03 million | Fiscal year 2019: $25.24 million | Fiscal year 2018: $19.59 million | Fiscal year 2017: $19.48 million | Fiscal year 2016: $16.39 million | Fiscal year 2015: $28.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: